Ignite Creation Date:
2024-05-05 @ 10:27 PM
Last Modification Date:
2024-10-26 @ 10:19 AM
Study NCT ID:
NCT01115738
Status:
COMPLETED
Last Update Posted:
2012-11-20
First Post:
2010-04-23
Brief Title:
Clopidogrel to Prasugrel in Acute Coronary Syndrome ACS Patients
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
TRansferring From ClopIdogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome PatiEnTs TRIPLET
Status:
COMPLETED
Status Verified Date:
2012-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the use of a prasugrel 60 mg loading dose LD administered during percutaneous coronary intervention PCI with and without a prior LD of clopidogrel on platelet inhibition in patients presenting with acute coronary syndrome ACS Platelet inhibition following a prasugrel LD in clopidogrel pretreated patients will be determined in a time-dependent manner for two different prasugrel loading doses 30 mg and 60 mg Understanding the effects of this combination on platelet inhibition will provide guidance to physicians on the use of prasugrel in patients who have already been pretreated with clopidogrel
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CTRI2010091000348 | REGISTRY | India | None |
| H7T-CR-TAEH | OTHER | None | None |